Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab

Andrew J. Barkmeier, Huseyin Kadikoy, Eric Holz, Petros E. Carvounis

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Purpose. To describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab. Methods. The medical records of a patient with peripheral exudative chorioretinopathy were reviewed. Results. Macular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course. Conclusions. Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.

Original languageEnglish (US)
Pages (from-to)506-508
Number of pages3
JournalEuropean Journal of Ophthalmology
Volume21
Issue number4
DOIs
StatePublished - Jul 1 2011

Keywords

  • Bevacizumab
  • Eccentric disciform degeneration
  • Eccentric retinal degeneration
  • Extramacular degeneration
  • Peripheral exudative hemorrhagic chorioretinopathy

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab'. Together they form a unique fingerprint.

Cite this